About US
Contact us
-
Merck to lay off 500 workers around the U.S. in continued shift to innovative medsMerck, like many of its Big Pharma peers,is working to focus more on innovative drugs. But as part of that ongoing shift, the company is eliminating 500 positions nationwide. The company is cuttingjo2019/10/28
-
J&J reels after FDA finds 'sub-trace' levels of asbestos in its baby powderFor years, J&J has defended against lawsuits linking its talcum powder to cancer by saying the products are safe and don't contain asbestos.But Friday, J&J issued a recall, sayingthe FDA had2019/10/25
-
Pfizer, GSK, others face negligence suits over Zantac carcinogen testingDrugmakers are scrambling to pull Zantac off the shelves after a possible carcinogen was found in the heartburn med’s API. Now, a suite of federal lawsuits are claiming four companies declined to tes2019/10/25
-
Novartis' Zolgensma beats data woe, as Mayzent hits reimbursement hurdlesDespite initial payer resistance and lingering questions about possible regulatory crackdown on Novartis after the Zolgensma data manipulation scandal, the costly spinal muscular atrophy gene therapy2019/10/24
-
BMS nets another Opdivo lung cancer win—but it still has to beat Merck's high barIt’s been a rocky road for Bristol-Myers Squibb’s immuno-oncology duo in previously untreated non-small cell lung cancer (NSCLC), but a new addition to the regimen might hold the ticket. Tuesday, the2019/10/24
-
Vertex lands $6B-plus triple combo nod for CF drug Trikafta—5 months earlyThe triple combo era in cystic fibrosis is here thanks to a Monday Vertex Pharmaceuticals approval—and it’s here earlier than industry watchers expected. A lot earlier. Five months ahead of schedule—2019/10/23
-
J&J, Teva offer a whopping $48B combined to wrap opioid suits, but not all plaintiffs are on boardInstead of facing the courtroom in an Ohio bellwether opioid trial, Johnson & Johnson and Teva opted to settle instead. But those deals are just two pieces of a much bigger one in the works: The2019/10/23
-
J&J's Stelara clinches ulcerative colitis nod to back up declining RemicadeUnder assault from newer therapies in the anti-inflammatory market, Johnson & Johnson has focused on expanding Stelara beyond dermatology—and Monday, it took another big step in that direction. T2019/10/22
-
AstraZeneca's Farxiga nabs first CV approval from the FDA. Will a bigger one follow?The Holy Grail for AstraZeneca’s SGLT2 med Farxiga is an approval to treat heart failure in patients with or without diabetes—and it’s well on its way to that goal. But while it waits for that game-c2019/10/22
-
FiercePharmaPolitics—Democrats to name pricing bill in Elijah Cummings' honorWelcome to theFiercePharmapolitical roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewherethat could affect howdrugmakersoperate. Aspricing debates rage on, the U.2019/10/21